全文获取类型
收费全文 | 463篇 |
免费 | 38篇 |
专业分类
耳鼻咽喉 | 18篇 |
儿科学 | 19篇 |
妇产科学 | 5篇 |
基础医学 | 50篇 |
口腔科学 | 9篇 |
临床医学 | 24篇 |
内科学 | 46篇 |
皮肤病学 | 4篇 |
神经病学 | 138篇 |
特种医学 | 6篇 |
外科学 | 55篇 |
综合类 | 16篇 |
预防医学 | 14篇 |
眼科学 | 13篇 |
药学 | 46篇 |
中国医学 | 2篇 |
肿瘤学 | 36篇 |
出版年
2023年 | 4篇 |
2022年 | 7篇 |
2021年 | 19篇 |
2020年 | 10篇 |
2019年 | 11篇 |
2018年 | 16篇 |
2017年 | 9篇 |
2016年 | 6篇 |
2015年 | 13篇 |
2014年 | 21篇 |
2013年 | 18篇 |
2012年 | 42篇 |
2011年 | 37篇 |
2010年 | 23篇 |
2009年 | 23篇 |
2008年 | 14篇 |
2007年 | 27篇 |
2006年 | 22篇 |
2005年 | 14篇 |
2004年 | 17篇 |
2003年 | 9篇 |
2002年 | 24篇 |
2001年 | 12篇 |
2000年 | 9篇 |
1999年 | 3篇 |
1998年 | 4篇 |
1997年 | 3篇 |
1996年 | 2篇 |
1995年 | 2篇 |
1994年 | 2篇 |
1993年 | 3篇 |
1992年 | 4篇 |
1991年 | 8篇 |
1990年 | 5篇 |
1989年 | 7篇 |
1988年 | 5篇 |
1987年 | 6篇 |
1986年 | 7篇 |
1985年 | 6篇 |
1984年 | 6篇 |
1982年 | 2篇 |
1980年 | 1篇 |
1979年 | 4篇 |
1976年 | 2篇 |
1975年 | 2篇 |
1974年 | 1篇 |
1973年 | 2篇 |
1972年 | 4篇 |
1971年 | 1篇 |
1901年 | 1篇 |
排序方式: 共有501条查询结果,搜索用时 15 毫秒
1.
Michael M Gezalian Luigi Mangiacotti Padmesh Rajput Nicklaus Sparrow Konrad Schlick Shouri Lahiri 《Journal of cerebral blood flow and metabolism》2021,41(4):693
Adrenoceptor and calcium channel modulating medications are widely used in clinical practice for acute neurological and systemic conditions. It is generally assumed that the cerebrovascular effects of these drugs mirror that of their systemic effects – and this is reflected in how these medications are currently used in clinical practice. However, recent research suggests that there are distinct cerebrovascular-specific effects of these medications that are related to the unique characteristics of the cerebrovascular anatomy including the regional heterogeneity in density and distribution of adrenoceptor subtypes and calcium channels along the cerebrovasculature. In this review, we critically evaluate existing basic science and clinical research to discuss known and putative interactions between adrenoceptor and calcium channel modulating pharmacotherapies, the neurovascular unit, and cerebrovascular anatomy. In doing so, we provide a rationale for selecting vasoactive medications based on lesion location and lay a foundation for future investigations that will define neuroprotective paradigms of adrenoceptor and calcium channel modulating therapies to improve neurological outcomes in acute neurological and systemic disorders. 相似文献
2.
A. H. Rajput 《Annals of neurology》1996,40(6):950-950
3.
Clinical and Epidemiological Relevance of Quantitating Hepatitis E Virus-Specific Immunoglobulin M 下载免费PDF全文
Jitvimol Seriwatana Mrigendra P. Shrestha Robert M. Scott Sergei A. Tsarev David W. Vaughn Khin Saw Aye Myint Bruce L. Innis 《Clinical and Vaccine Immunology : CVI》2002,9(5):1072-1078
Diagnosis of acute hepatitis E by detection of hepatitis E virus (HEV)-specific immunoglobulin M (IgM) is an established procedure. We investigated whether quantitation of HEV IgM and its ratio to HEV total Ig furnished more information than conventional IgM tests that are interpreted as positive or negative. A previously described indirect immunoassay for total Ig against a baculovirus-expressed HEV capsid protein was modified to quantitate HEV-specific IgM in Walter Reed (WR) antibody units by using a reference antiserum and the four-parameter logistic model. A receiver-operating characteristics curve derived from 197 true-positive specimens and 449 true-negative specimens identified 30 WR units/ml as an optimum cut point. The median HEV IgM level in 36 patients with acute hepatitis E fell from 3,000 to 100 WR units/ml over 6 months, suggesting that 100 WR units/ml would be a more appropriate cut point for distinguishing recent from remote IgM responses. Among three hepatitis E case series, determination of the HEV IgM-to-total-Ig ratio in acute-phase serum revealed that most patients had high ratios consistent with primary infections whereas a few had low ratios, suggesting that they had sustained reinfections that elicited anamnestic antibody responses. The diagnostic utility of the new IgM test was similar to that of a commercially available test that uses different HEV antigens. In conclusion, we found that HEV IgM can be detected specifically in >95% of acute hepatitis E cases defined by detection of the virus genome in serum and that quantitation of HEV IgM and its ratio to total Ig provides insight into infection timing and prior immunity. 相似文献
4.
5.
R. C. Yadav Chanchal Rajput S. P. Srivastava H. K. Kukreja 《Indian journal of otolaryngology and head and neck surgery》1985,37(4):163-164
A case of Primary Carcinoma of the Frontal Sinus. 相似文献
6.
7.
8.
9.
Alex Rajput Jay P Ross Cecily Q Bernales Sruti Rayaprolu Alexandra I Soto-Ortolaza Owen A Ross Jay van Gerpen Ryan J Uitti Zbigniew K Wszolek Ali H Rajput Carles Vilari?o-Güell 《European journal of human genetics : EJHG》2015,23(6):887-888
Exome-sequencing analyses have identified vacuolar protein sorting 35 homolog (VPS35) and DnaJ (Hsp40) homolog, subfamily C, member 13 (DNAJC13) harboring disease-causing variants for Parkinson disease (PD). Owing to the suggested clinical, pathological and genetic overlap between PD and essential tremor (ET) we assessed the presence of two VPS35 and DNAJC13 disease-causing variants in ET patients. TaqMan probes were used to genotype VPS35 c.1858G>A (p.(D620N)) (rs188286943) and DNAJC13 c.2564A>G (p.(N855S)) (rs387907571) in 571 ET patients of European descent, and microsatellite markers were used to define the disease haplotype in variant carriers. Genotyping of DNAJC13 identified two ET patients harboring the c.2564A>G (p.(N855S)) variant previously identified in PD patients. Both patients appear to share the disease haplotype previously reported. ET patients with the VPS35 c.1858G>A (p.(D620N)) variants were not observed. Although a genetic link between PD and ET has been suggested, DNAJC13 c.2564A>G (p.(N855S)) represents the first disease-causing variant identified in both, and suggests the regulation of clathrin dynamics and endosomal trafficking in the pathophysiology of a subset of ET patients. 相似文献
10.
Kathryn Fitch Thomas Weisman Tyler Engel Adam Turpcu Helen Blumen Yamina Rajput Purav Dave 《American Health & Drug Benefits》2015,8(6):300-308